 | • レポートコード：MRC2307A0180 • 出版社/出版日：Transparency Market Research / 2023年4月 • レポート形態：英文、PDF、256ページ • 納品方法：Eメール • 産業分類：医療 |
| Single User | ￥869,250 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,319,250 (USD8,795) | ▷ お問い合わせ |
| Corporate License | ￥1,769,250 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Transparency Market Research社の本報告書は、世界のウイルスベクター製造市場規模が、2023年の167億ドルから予測期間中、年平均4.4％で成長し、2031年には173億ドルに達すると予測しています。本書は、序論、仮定＆調査手法、エグゼクティブサマリー、市場概要、キーインサイト、ベクター種類別（アデノウイルス、アデノ随伴ウイルス、レトロウイルス、その他）分析、疾患別（遺伝病、感染症、がん、その他）分析、用途別（遺伝子治療、ワクチン）分析、モード別（一過性トランスフェクション、安定生産細胞株）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況などの構成でまとめています。なお、当市場の主要企業には、Pfizer, Inc.、Johnson & Johnson、AstraZeneca、Sanofi、Novartis AG、Spark Therapeutics, Inc. (F. Hoffmann-La Roche Ltd.)、GlaxoSmithKline plc、Merck KGaA (Merck & Co., Inc.)、Lonza、FUJIFILM Diosynth Biotechnologies, Inc.、Oxford Biomedica plc、Amgen, Inc.、Ferring B.V.、uniQure N.V.、bluebird bio, Inc.、GenScript ProBioなどがあります。 ・序論 ・仮定＆調査手法 ・エグゼクティブサマリー ・市場概要 ・キーインサイト ・世界のウイルスベクター製造市場規模：ベクター種類別 - アデノウイルスの市場規模 - アデノ随伴ウイルスの市場規模 - レトロウイルスの市場規模 - その他ベクターの市場規模 ・世界のウイルスベクター製造市場規模：疾患別 - 遺伝病における市場規模 - 感染症における市場規模 - がんにおける市場規模 - その他疾患における市場規模 ・世界のウイルスベクター製造市場規模：用途別 - 遺伝子治療用ウイルスベクター製造の市場規模 - ワクチン用ウイルスベクター製造の市場規模 ・世界のウイルスベクター製造市場規模：モード別 - 一過性トランスフェクションの市場規模 - 安定生産細胞株の市場規模 ・世界のウイルスベクター製造市場規模：地域別 - 北米のウイルスベクター製造市場規模 - ヨーロッパのウイルスベクター製造市場規模 - アジア太平洋のウイルスベクター製造市場規模 - 中南米のウイルスベクター製造市場規模 - 中東・アフリカのウイルスベクター製造市場規模 ・競争状況 |
Viral Vector Production Market – Scope of Report
TMR’s report on the global Viral Vector Production Market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global Viral Vector Production Market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global Viral Vector Production Market from 2023 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the Plasmonic Materials market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global Plasmonic Materials market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global Plasmonic Materials market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global Plasmonic Materials market.
The report delves into the competitive landscape of the global Plasmonic Materials market. Key players operating in the global Viral Vector Production Market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global Viral Vector Production Market profiled in this report.
Key Questions Answered in Global Viral Vector Production Market Report
• What is the sales/revenue generated by Plasmonic Materials across all regions during the forecast period?
• What are the opportunities in the global Plasmonic Materials market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?
Viral Vector Production Market – Research Objectives and Research Approach
The comprehensive report on the global Viral Vector Production Market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global Viral Vector Production Market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global Plasmonic Materials market.
レポート目次1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Viral Vector Production Market
4. Market Overview
4.1. Introduction
4.1.1. Vector Type Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Viral Vector Production Market Analysis and Forecast, 2017-2031
5. Key Insights
5.1. Evolution of Gene Therapy
5.2. Pipeline Analysis
5.3. Regulatory Scenario, by Region/Globally
5.4. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)
6. Global Viral Vector Production Market Analysis and Forecast, by Vector Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Vector Type, 2017-2031
6.3.1. Adenovirus
6.3.2. Adeno-associated virus
6.3.3. Retroviruses
6.3.4. Others (baculoviruses, lentivirus, etc.)
6.4. Market Attractiveness Analysis, by Vector Type
7. Global Viral Vector Production Market Analysis and Forecast, by Disease
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Disease, 2017-2031
7.3.1. Genetic Diseases
7.3.2. Infectious Diseases
7.3.3. Cancer
7.3.4. Others (metabolic diseases, neurodegenerative disorders, etc.)
7.4. Market Attractiveness Analysis, by Disease
8. Global Viral Vector Production Market Analysis and Forecast, by Application
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Application, 2017-2031
8.3.1. Gene Therapy
8.3.2. Vaccinology
8.4. Market Attractiveness Analysis, by Application
9. Global Viral Vector Production Market Analysis and Forecast, by Mode
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast, by Mode, 2017-2031
9.3.1. Transient Transfection
9.3.2. Stable Producer Cell Lines
9.4. Market Attractiveness Analysis, by Mode
10. Global Viral Vector Production Market Analysis and Forecast, by End-user
10.1. Introduction & Definition
10.2. Key Findings / Developments
10.3. Market Value Forecast, by End-user, 2017-2031
10.3.1. Pharmaceutical & Biotechnology Companies
10.3.2. Academic & Research Institutes
10.3.3. CROs & CDMOs
10.4. Market Attractiveness Analysis, by End-user
11. Global Viral Vector Production Market Analysis and Forecast, by Region
11.1. Key Findings
11.2. Market Value Forecast, by Region
11.2.1. North America
11.2.2. Europe
11.2.3. Asia Pacific
11.2.4. Latin America
11.2.5. Middle East & Africa
11.3. Market Attractiveness Analysis, by Region
12. North America Viral Vector Production Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Vector Type, 2017-2031
12.2.1. Adenovirus
12.2.2. Adeno-associated virus
12.2.3. Retroviruses
12.2.4. Others (baculoviruses, lentivirus, etc.)
12.3. Market Value Forecast, by Disease, 2017-2031
12.3.1. Genetic Diseases
12.3.2. Infectious Diseases
12.3.3. Cancer
12.3.4. Others (metabolic diseases, neurodegenerative disorders, etc.)
12.4. Market Value Forecast, by Application, 2017-2031
12.4.1. Gene Therapy
12.4.2. Vaccinology
12.5. Market Value Forecast, by Mode, 2017-2031
12.5.1. Transient Transfection
12.5.2. Stable Producer Cell Lines
12.6. Market Value Forecast, by End-user, 2017-2031
12.6.1. Pharmaceutical & Biotechnology Companies
12.6.2. Academic & Research Institutes
12.6.3. CROs & CDMOs
12.7. Market Value Forecast, by Country, 2017-2031
12.7.1. U.S.
12.7.2. Canada
12.8. Market Attractiveness Analysis
12.8.1. By Vector Type
12.8.2. By Disease
12.8.3. By Application
12.8.4. By Mode
12.8.5. By End-user
12.8.6. By Country
13. Europe Viral Vector Production Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Vector Type, 2017-2031
13.2.1. Adenovirus
13.2.2. Adeno-associated virus
13.2.3. Retroviruses
13.2.4. Others (baculoviruses, lentivirus, etc.)
13.3. Market Value Forecast, by Disease, 2017-2031
13.3.1. Genetic Diseases
13.3.2. Infectious Diseases
13.3.3. Cancer
13.3.4. Others (metabolic diseases, neurodegenerative disorders, etc.)
13.4. Market Value Forecast, by Application, 2017-2031
13.4.1. Gene Therapy
13.4.2. Vaccinology
13.5. Market Value Forecast, by Mode, 2017-2031
13.5.1. Transient Transfection
13.5.2. Stable Producer Cell Lines
13.6. Market Value Forecast, by End-user, 2017-2031
13.6.1. Pharmaceutical & Biotechnology Companies
13.6.2. Academic & Research Institutes
13.6.3. CROs & CDMOs
13.7. Market Value Forecast, by Country/Sub-region, 2017-2031
13.7.1. Germany
13.7.2. U.K.
13.7.3. France
13.7.4. Spain
13.7.5. Italy
13.7.6. Rest of Europe
13.8. Market Attractiveness Analysis
13.8.1. By Vector Type
13.8.2. By Disease
13.8.3. By Application
13.8.4. By Mode
13.8.5. By End-user
13.8.6. By Country/Sub-region
14. Asia Pacific Viral Vector Production Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Vector Type, 2017-2031
14.2.1. Adenovirus
14.2.2. Adeno-associated virus
14.2.3. Retroviruses
14.2.4. Others (baculoviruses, lentivirus, etc.)
14.3. Market Value Forecast, by Diseases, 2017-2031
14.3.1. Genetic Diseases
14.3.2. Infectious Diseases
14.3.3. Cancer
14.3.4. Others (metabolic diseases, neurodegenerative disorders, etc.)
14.4. Market Value Forecast, by Application, 2017-2031
14.4.1. Gene Therapy
14.4.2. Vaccinology
14.5. Market Value Forecast, by Mode, 2017-2031
14.5.1. Transient Transfection
14.5.2. Stable Producer Cell Lines
14.6. Market Value Forecast, by End-user, 2017-2031
14.6.1. Pharmaceutical & Biotechnology Companies
14.6.2. Academic & Research Institutes
14.6.3. CROs & CDMOs
14.7. Market Value Forecast, by Country/Sub-region, 2017-2031
14.7.1. China
14.7.2. Japan
14.7.3. India
14.7.4. Australia & New Zealand
14.7.5. Rest of Asia Pacific
14.8. Market Attractiveness Analysis
14.8.1. By Vector Type
14.8.2. By Disease
14.8.3. By Application
14.8.4. By Mode
14.8.5. By End-user
14.8.6. By Country/Sub-region
15. Latin America Viral Vector Production Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Vector Type, 2017-2031
15.2.1. Adenovirus
15.2.2. Adeno-associated virus
15.2.3. Retroviruses
15.2.4. Others (baculoviruses, lentivirus, etc.)
15.3. Market Value Forecast, by Disease, 2017-2031
15.3.1. Genetic Diseases
15.3.2. Infectious Diseases
15.3.3. Cancer
15.3.4. Others (metabolic diseases, neurodegenerative disorders, etc.)
15.4. Market Value Forecast, by Application, 2017-2031
15.4.1. Gene Therapy
15.4.2. Vaccinology
15.5. Market Value Forecast, by Mode, 2017-2031
15.5.1. Transient Transfection
15.5.2. Stable Producer Cell Lines
15.6. Market Value Forecast, by End-user, 2017-2031
15.6.1. Pharmaceutical & Biotechnology Companies
15.6.2. Academic & Research Institutes
15.6.3. CROs & CDMOs
15.7. Market Value Forecast, by Country/Sub-region, 2017-2031
15.7.1. Brazil
15.7.2. Mexico
15.7.3. Rest of Latin America
15.8. Market Attractiveness Analysis
15.8.1. By Vector Type
15.8.2. By Disease
15.8.3. By Application
15.8.4. By Mode
15.8.5. By End-user
15.8.6. By Country/Sub-region
16. Middle East & Africa Viral Vector Production Market Analysis and Forecast
16.1. Introduction
16.1.1. Key Findings
16.2. Market Value Forecast, by Vector Type, 2017-2031
16.2.1. Adenovirus
16.2.2. Adeno-associated virus
16.2.3. Retroviruses
16.2.4. Others (baculoviruses, lentivirus, etc.)
16.3. Market Value Forecast, by Disease, 2017-2031
16.3.1. Genetic Diseases
16.3.2. Infectious Diseases
16.3.3. Cancer
16.3.4. Others (metabolic diseases, neurodegenerative disorders, etc.)
16.4. Market Value Forecast, by Application, 2017-2031
16.4.1. Gene Therapy
16.4.2. Vaccinology
16.5. Market Value Forecast, by Mode, 2017-2031
16.5.1. Transient Transfection
16.5.2. Stable Producer Cell Lines
16.6. Market Value Forecast, by End-user, 2017-2031
16.6.1. Pharmaceutical & Biotechnology Companies
16.6.2. Academic & Research Institutes
16.6.3. CROs & CDMOs
16.7. Market Value Forecast, by Country/Sub-region, 2017-2031
16.7.1. GCC Countries
16.7.2. South Africa
16.7.3. Rest of Middle East & Africa
16.8. Market Attractiveness Analysis
16.8.1. By Vector Type
16.8.2. By Disease
16.8.3. By Application
16.8.4. By Mode
16.8.5. By End-user
16.8.6. By Country/Sub-region
17. Competition Landscape
17.1. Market Player – Competition Matrix (By Tier and Size of companies)
17.2. Market Share Analysis By Company (2021)
17.3. Company Profiles
17.3.1. Pfizer, Inc.
17.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.1.2. Test Type Portfolio
17.3.1.3. Financial Overview
17.3.1.4. SWOT Analysis
17.3.1.5. Strategic Overview
17.3.2. Johnson & Johnson
17.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.2.2. Test Type Portfolio
17.3.2.3. Financial Overview
17.3.2.4. SWOT Analysis
17.3.2.5. Strategic Overview
17.3.3. AstraZeneca
17.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.3.2. Test Type Portfolio
17.3.3.3. Financial Overview
17.3.3.4. SWOT Analysis
17.3.3.5. Strategic Overview
17.3.4. Sanofi
17.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.4.2. Test Type Portfolio
17.3.4.3. Financial Overview
17.3.4.4. SWOT Analysis
17.3.4.5. Strategic Overview
17.3.5. Novartis AG
17.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.5.2. Test Type Portfolio
17.3.5.3. Financial Overview
17.3.5.4. SWOT Analysis
17.3.5.5. Strategic Overview
17.3.6. Spark Therapeutics, Inc. (F. Hoffmann-La Roche Ltd.)
17.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.6.2. Test Type Portfolio
17.3.6.3. Financial Overview
17.3.6.4. SWOT Analysis
17.3.6.5. Strategic Overview
17.3.7. GlaxoSmithKline plc
17.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.7.2. Test Type Portfolio
17.3.7.3. Financial Overview
17.3.7.4. SWOT Analysis
17.3.7.5. Strategic Overview
17.3.8. Merck KGaA (Merck & Co., Inc.)
17.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.8.2. Test Type Portfolio
17.3.8.3. Financial Overview
17.3.8.4. SWOT Analysis
17.3.8.5. Strategic Overview
17.3.9. Lonza
17.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.9.2. Test Type Portfolio
17.3.9.3. Financial Overview
17.3.9.4. SWOT Analysis
17.3.9.5. Strategic Overview
17.3.10. FUJIFILM Diosynth Biotechnologies Inc.
17.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.10.2. Test Type Portfolio
17.3.10.3. Financial Overview
17.3.10.4. SWOT Analysis
17.3.10.5. Strategic Overview
17.3.11. Oxford Biomedica plc
17.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.11.2. Test Type Portfolio
17.3.11.3. Financial Overview
17.3.11.4. SWOT Analysis
17.3.11.5. Strategic Overview
17.3.12. Amgen Inc.
17.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.12.2. Test Type Portfolio
17.3.12.3. Financial Overview
17.3.12.4. SWOT Analysis
17.3.12.5. Strategic Overview
17.3.13. Ferring B.V.
17.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.13.2. Test Type Portfolio
17.3.13.3. Financial Overview
17.3.13.4. SWOT Analysis
17.3.13.5. Strategic Overview
17.3.14. uniQure N.V.
17.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.14.2. Test Type Portfolio
17.3.14.3. Financial Overview
17.3.14.4. SWOT Analysis
17.3.14.5. Strategic Overview
17.3.15. bluebird bio, Inc.
17.3.15.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.15.2. Test Type Portfolio
17.3.15.3. Financial Overview
17.3.15.4. SWOT Analysis
17.3.15.5. Strategic Overview
17.3.16. GenScript ProBio
17.3.16.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.16.2. Test Type Portfolio
17.3.16.3. Financial Overview
17.3.16.4. SWOT Analysis
17.3.16.5. Strategic Overview
17.3.17. Thermo Fisher Scientific, Inc.
17.3.17.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.17.2. Test Type Portfolio
17.3.17.3. Financial Overview
17.3.17.4. SWOT Analysis
17.3.17.5. Strategic Overview
17.3.18. Gamaleya Research Institute
17.3.18.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.18.2. Test Type Portfolio
17.3.18.3. Financial Overview
17.3.18.4. SWOT Analysis
17.3.18.5. Strategic Overview
Table 01: Global Viral Vector Production Market Value (US$ Mn) Forecast, by Vector Type, 2017-2032
Table 02: Global Viral Vector Production Market Value (US$ Mn) Forecast, by Disease, 2017-2032
Table 03: Global Viral Vector Production Market Value (US$ Mn) Forecast, by Application, 2017-2032
Table 04: Global Viral Vector Production Market Value (US$ Mn) Forecast, by Mode, 2017-2032
Table 05: Global Viral Vector Production Market Value (US$ Mn) Forecast, by End-user, 2017-2032
Table 06: Global Viral Vector Production Market Value (US$ Mn) Forecast, by Region, 2017-2032
Table 07: North America Viral Vector Production Market Value (US$ Mn) Forecast, by Country, 2017-2032
Table 08: North America Viral Vector Production Market Value (US$ Mn) Forecast, by Vector Type, 2017-2032
Table 09: North America Viral Vector Production Market Value (US$ Mn) Forecast, by Disease, 2017-2032
Table 10: North America Viral Vector Production Market Value (US$ Mn) Forecast, by Application, 2017-2032
Table 11: North America Viral Vector Production Market Value (US$ Mn) Forecast, by Mode, 2017-2032
Table 12: North America Viral Vector Production Market Value (US$ Mn) Forecast, by End-user, 2017-2032
Table 13: Europe Viral Vector Production Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2032
Table 14: Europe Viral Vector Production Market Value (US$ Mn) Forecast, by Vector Type, 2017-2032
Table 15: Europe Viral Vector Production Market Value (US$ Mn) Forecast, by Disease, 2017-2032
Table 16: Europe Viral Vector Production Market Value (US$ Mn) Forecast, by Application, 2017-2032
Table 17: Europe Viral Vector Production Market Value (US$ Mn) Forecast, by Mode, 2017-2032
Table 18: Europe Viral Vector Production Market Value (US$ Mn) Forecast, by End-user, 2017-2032
Table 19: Asia Pacific Viral Vector Production Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2032
Table 20: Asia Pacific Viral Vector Production Market Value (US$ Mn) Forecast, by Vector Type, 2017-2032
Table 21: Asia Pacific Viral Vector Production Market Value (US$ Mn) Forecast, by Disease, 2017-2032
Table 22: Asia Pacific Viral Vector Production Market Value (US$ Mn) Forecast, by Application, 2017-2032
Table 23: Asia Pacific Viral Vector Production Market Value (US$ Mn) Forecast, by Mode, 2017-2032
Table 24: Asia Pacific Viral Vector Production Market Value (US$ Mn) Forecast, by End-user, 2017-2032
Table 25: Latin America Viral Vector Production Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2032
Table 26: Latin America Viral Vector Production Market Value (US$ Mn) Forecast, by Vector Type, 2017-2032
Table 27: Latin America Viral Vector Production Market Value (US$ Mn) Forecast, by Disease, 2017-2032
Table 28: Latin America Viral Vector Production Market Value (US$ Mn) Forecast, by Application, 2017-2032
Table 29: Latin America Viral Vector Production Market Value (US$ Mn) Forecast, by Mode, 2017-2032
Table 30: Latin America Viral Vector Production Market Value (US$ Mn) Forecast, by End-user, 2017-2032
Table 31: Middle East & Africa Viral Vector Production Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2032
Table 32: Middle East & Africa Viral Vector Production Market Value (US$ Mn) Forecast, by Vector Type, 2017-2032
Table 33: Middle East & Africa Viral Vector Production Market Value (US$ Mn) Forecast, by Disease, 2017-2032
Table 34: Middle East & Africa Viral Vector Production Market Value (US$ Mn) Forecast, by Application, 2017-2032
Table 35: Middle East & Africa Viral Vector Production Market Value (US$ Mn) Forecast, by Mode, 2017-2032
Table 36: Middle East & Africa Viral Vector Production Market Value (US$ Mn) Forecast, by End-user, 2017-2032